US Patent Issued to University of Pittsburgh-Of the Commonwealth System on July 29 for "Use of eomesodermin to determine risk of allograft rejection" (Pennsylvania Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,372,513, issued on July 29, was assigned to University of Pittsburgh-Of the Commonwealth System (Pittsburgh).

"Use of eomesodermin to determine risk of allograft rejection" was invented by Mohamed B. Ezzelarab (Pittsburgh) and Angus W. Thomson (Pittsburgh).

According to the abstract* released by the U.S. Patent & Trademark Office: "Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to ...